Lipoprotein(a), an atherogenic lipoprotein consisting of apoplipoprotein(a) [apo(a)]
covalently bound to apolipoprotein B-100 of low density lipoproteins (LDL), is a prevalent genetic risk factor for cardiovascular disease. Several genome wide association studies (GWAS) have established an association between single nucleotide polymorphisms (SNPs) in LPA, the gene encoding apo(a), and coronary artery disease (CAD) and myocardial infarction (MI) (1) (2) (3) .
Moreover, recent Mendelian randomization studies also demonstrate that LPA SNPs associated with elevated plasma Lp(a) levels, also predict development of MI (4, 5) and aortic valve stenosis (6, 7) , supporting a role for Lp(a) as a genetically determined, independent, causal risk factor for these diseases. Elevated plasma Lp(a) is common, with 20% of the population having Lp(a) > 50mg/dl, levels consistently associated with approximately a two-fold increased risk of MI in large prospectively followed cohorts (8, 9) .
There have been several proposed mechanisms for the atherogenicity of Lp(a), including upregulation of endothelial cell adhesion molecules, activation of monocyte chemoattractant protein-1 (10), increasing endothelial cell permeability, cytokine release, macrophage apoptosis (11) , promoting smooth muscle cell proliferation, foam cell formation, and inhibition of fibrinolysis (reviewed in (12) ). Furthermore, Lp(a) is the major lipoprotein carrier of oxidized phospholipids (OxPL) (13) and carries these highly immunogenic and pro-inflammatory lipids on its LDL moiety as well as covalently bound to apo(a) (14) . Lp(a) and OxPL are found in human atheromas, but more importantly, they are enriched in more advanced plaque compared to early lesions (15). Lp(a) and OxPL are both potent stimulators of apoptosis in endoplasmic reticulum stressed macrophage in a scavenger receptor CD36 and Toll-like receptor 2 dependent pathway (16) . Monocyte chemoattractant protein-1 (MCP-1), an important chemokine implicated in the development of atherosclerosis, binds to oxidized LDL in an OxPL dependent manner, and by guest, on September 21, 2017 www.jlr.org Downloaded from is found on human Lp(a) as well (10) . As a clinical correlate to these basic investigations, OxPL measured on apolipoprotein B-100 (OxPL-apoB), which primarily reflect the content of OxPL on Lp(a), strongly predict anatomical disease in a variety of vascular beds as well as cardiovascular events such as cardiac death, MI, stroke and peripheral arterial disease (9, (17) (18) (19) (20) .
Although it is clear that elevated levels of Lp(a) increase the risk of cardiovascular disease, the relationship between Lp(a) and hazard ratio for incident CVD has been shown in some studies to be "J" shaped with decreased risk at low levels of Lp(a) (19, 21) , but higher risk in patients with very low or nearly absent Lp(a). For example, in the 4S trial, there was a graded increase in risk of cardiac death in the placebo group with increasing Lp(a) levels. However, in the simvastatin arm, although there was a reduction in cardiac mortality in the study as a whole, the greatest benefit was not seen in the lowest quartile but instead in the second quartile of Lp(a), with a relative 58% reduction. Unfortunately, due to arbitrary rather than absolute units of Lp(a) measurements, it's not possible to convert these data to mg/dL or nmol/L. In the Bruneck Study, a 'J" shape in risk of CVD and major adverse cardiac events was also noted, with patients having plasma levels between 2.7-6.8 mg/dL having the lowest risk, and patients with levels <2.7 mg/dL having similar numbers of events as those with levels 6.8-23.9 mg/dL, and the risk at higher levels rising significantly. In several studies, including the Emerging Risk Factors Collaboration analysis, a dip below an odds ratio of 1.00 was present for non-fatal MI and coronary and noncoronary death at approximately 8 mg/dL (22) . Finally, in studies of successful aging beyond age 83 or in centenarians, there is an over-representation of patients not in the lowest quartiles but instead in those with more modest elevations of plasma Lp(a) (23) (24) (25) . These phenomena are incompletely understood, but suggest potential beneficial effects of plasma Lp(a) at levels within transcript levels. In contrast, it was suggested that the effect appeared to be due to SR-B1 mediated internalization of the lipid content of Lp(a), and specifically OxPL within the lipid phase, as the addition of the monoclonal antibody E06, which specifically binds to the phosphocholine (PC) head group of oxidized but not native PC containing phospholipids (27) (28) (29) , abolished the upregulation of ABCA1 by Lp(a). However, experiments incubating Lp(a) with E06 alone to assess the effect on ABCA1 or on efflux capacity were not reported. antibody. This is consistent with in-vivo data demonstrating that apo(a) competitively inhibits the plasma clearance of Lp(a) in mice (36) . Although it has been more than 50 years since the discovery of Lp(a) (37) , the receptor(s) involved in Lp(a) uptake are still not well defined. Using how Lp(a) is catabolized. Although the data presented here in a cell culture model is convincing, the role of Lp(a) and its associated OxPL in cholesterol efflux in humans will need to be evaluated. One way this can be done is to examine large databases where plasma levels of Lp(a)
and OxPL-apoB can be correlated with reported cholesterol efflux assays and also linked to outcomes. Convincing data would be if Lp(a) positively correlated with cholesterol efflux and this in turn modified the risk of CVD mediated by Lp(a). However, because these assays deplete apoB prior to measurement of efflux (49) , and along with it Lp(a), they would not be informative as to a possible role of Lp(a) in modulating efflux. An alternative way to further study this would be to modify the current methodology by manipulating human plasma samples as agents for efflux from labelled cholesterol-loaded macrophages (49) . For example one could study efflux before and after selectively precipitating Lp(a) to determine its role, if any, in such efflux assays, and by omitting chemical upregulation of ABCA1, which is required for the Lp(a) mediated efflux described in this report. This will provide further understanding of the contribution of varying levels of plasma Lp(a) on cholesterol efflux in humans.
